<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947674</url>
  </required_header>
  <id_info>
    <org_study_id>NEWS80</org_study_id>
    <nct_id>NCT00947674</nct_id>
  </id_info>
  <brief_title>A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC)</brief_title>
  <official_title>Prospective, Randomized, Double-Blind, Sham Treatment Controlled Multicenter Study to Evaluate Efficacy and Safety of Cellsorbaâ„¢EX Used for Leukocytapheresis (LCAP) in Patients With Steroid-Free, Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asahi Kasei Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asahi Kasei Medical Europe GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asahi Kasei Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, sham treatment controlled multicenter study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    short of enrollment
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>at 8th week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission, Mayo scores, Mucosal healing, CRP</measure>
    <time_frame>at 8th and 16th week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Cellsorba EX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cellsorba EX</intervention_name>
    <description>conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times</description>
    <arm_group_label>Cellsorba EX</arm_group_label>
    <arm_group_label>Sham treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed to have UC in the active stage based on clinical symptoms and
             findings from endoscopy

          -  Patients with pancolitis type or left-sided colitis type lesion of 15 cm or longer
             observed endoscopically

          -  Patients with Mayo score between 5 and 10

          -  Patients with Mayo sub-score (findings from flexible sigmoidoscopy) of 2 or 3

          -  Patients not having received any corticosteroids (referred to as steroids) (p.o.,
             i.v., enema, suppository) within the past 6 weeks

        Exclusion Criteria:

          -  Patients with a difficulty in peripheral vascular access

          -  Patients having received ACE inhibitor (at least 10 times of its half-life time for
             interval needed before initiating the treatment)

          -  Patients with toxic megacolon

          -  Patients with a malignant disease or its experience

          -  Patients with a severe cardiovascular disease (grade III or IV by the Classification
             of heart functions of the New York Heart Association (NYHA))

          -  Patients with a liver or kidney disease (AST(GOT) or ALT(GPT) or total bilirubin or
             creatinine level which is 2 or more times higher than the upper limit of normal
             (abbreviated as ULN, hereinafter)

          -  Patients suspected to have or having HBV or HCV or HIV or pathogenic bacteria

          -  Patients on anticoagulant therapy or with abnormality in the blood coagulation system
             (PT or PTT levels which are 1.5 or more times higher than ULN

          -  Pregnant women or patients with possible pregnancy

          -  Breast feeding women

          -  Patients weighing 40 kg or less

          -  Patients with hemoglobin level of less than 6.5 mmol/L (10.5 g/dL)

          -  Patients with platelet count of less than 150 x 103/mm3, 150 x 109/L (15 x 104/mm3)

          -  Patients with white blood cell count of less than 3.5 x 109/L (3,500/mm3)

          -  Patients with hypotension (with systolic blood pressure of 80 mmHg or less)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2009</study_first_submitted>
  <study_first_submitted_qc>July 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2009</study_first_posted>
  <last_update_submitted>December 5, 2012</last_update_submitted>
  <last_update_submitted_qc>December 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cellsorba EX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

